SCHEMBL2932229

SCHEMBL2932229

Cc1ncc2c(c1O)C(=O)OC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
P2RX3 P56373 1/20 0.45
NUAK1 O60285 1/20 0.42
IGF1R P08069 1/20 0.42
MET P08581 1/20 0.42
PIM1 P11309 1/20 0.42
SRC P12931 1/20 0.42
AXL P30530 1/20 0.42
AKT1 P31749 1/20 0.42
KDR P35968 1/20 0.42
NEK2 P51955 1/20 0.42
PLK1 P53350 1/20 0.42
PTK2 Q05397 1/20 0.42
PKN1 Q16512 1/20 0.42
AURKB Q96GD4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11625767 0.98 KDM4E (0.44) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL13176559 0.82 KDM4E (0.37) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL11625625 0.77 KDM4E (0.54) KDM4EKMT2ANUAK1IGF1RMET
SCHEMBL12444323 0.72 KDM4E (0.45) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL16870479 0.71 KDM4E (0.47) KDM4EKMT2AMEN1NUAK1IGF1R
SCHEMBL6062280 0.68 NUAK1 (0.41) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL9606823 0.68 NUAK1 (0.41) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL30048869 0.68 KDM4E (0.44) KDM4EGAASMN1; SMN2ALDH1A1HPGD
SCHEMBL15680616 0.67 KDM4E (0.46) KDM4EKMT2AMEN1NUAK1IGF1R
SCHEMBL23857115 0.66 ALDH1A1 (0.40) KDM4EKMT2AMEN1NUAK1IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5421337-A To determine the presence of abnormal tissue MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1995-06-06 US claimed
CN-119601089-A Urine endogenous metabolism marker and application thereof 中国人民解放军海军军医大学第二附属医院 2025-03-11 CN disclosed
EP-2230312-A1 Probe compound for detecting and isolating enzymes and means and methods using the same Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2010-09-22 EP disclosed
US-20080311099-A1 Pyridoxal-5-Phosphate and Related Compounds in Combination With Therapeutic Cardiovascular Compounds for Treating Angina MEDICURE INTERNATIONAL INC. 2008-12-18 US disclosed
WO-2007121588-A1 TREATMENT OF ATRIAL FIBRILLATION MEDICURE INTERNATIONAL INC. (BB) 2007-11-01 WO disclosed
US-20070249562-A1 TREATMENT OF ATRIAL FIBRILLATION MEDICURE INTERNATIONAL INC. (CA) 2007-10-25 US disclosed
US-20070167411-A1 Compositions for treating angina MEDICURE INTERNATIONAL INC. (BB) 2007-07-19 US disclosed
US-20070032456-A1 Modulation of cell death MEDICURE INC. (CA) 2007-02-08 US disclosed
JP-2006238808-A NEW PYRIDOXAL 4-DEHYDROGENASE AND ITS UTILIZATION KOCHI UNIV 2006-09-14 JP disclosed
EP-1610783-A2 MODULATION OF CELL DEATH Medicure Inc. (CA) 2006-01-04 EP disclosed
EP-1608379-A1 COMPOSITIONS FOR TREATING ANGINA Medicure Inc. (CA) 2005-12-28 EP disclosed
WO-2004084910-A1 COMPOSITIONS FOR TREATING ANGINA MEDICURE INC. (CA) 2004-10-07 WO disclosed
WO-2004084895-A2 MODULATION OF CELL DEATH MEDICURE, INC. (CA) 2004-10-07 WO disclosed
US-5421337-A To determine the presence of abnormal tissue MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1995-06-06 US disclosed
EP-0466828-A1 SPECTRAL DIAGNOSIS OF DISEASED TISSUE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1992-01-22 EP disclosed
WO-1990012536-A1 SPECTRAL DIAGNOSIS OF DISEASED TISSUE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1990-11-01 WO disclosed
US-4070450-A Sunscreening compound and method HOFFMANN-LA ROCHE, INC. (US) 1978-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249562-A1 TREATMENT OF ATRIAL FIBRILLATION PNPO, KCNH1, PLPBP KDM4E 1940/4885KMT2A 3014/4885MEN1 2331/4885
US-20070167411-A1 Compositions for treating angina PNPO, PYGM, PLPBP KDM4E 2123/4885KMT2A 3440/4885MEN1 3967/4885
US-20080311099-A1 Pyridoxal-5-Phosphate and Related Compounds in Combination With Therapeutic Cardiovascular Compounds for Treating Angina ALOX5, PNPO, KCNMB1 KDM4E 1392/4885KMT2A 2206/4885MEN1 4725/4885
US-20070032456-A1 Modulation of cell death CASP6, CASP3, CASP5 KDM4E 1592/4885KMT2A 4133/4885MEN1 3529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.